Drug developers sit on enormous volumes of clinical, genomic, commercial and real-world data, but most of it sits in disconnected systems. The companies that connect it, trust it and act on it faster will shorten development timelines and win on launch. That is the premise behind the life sciences data intelligence market.
The global market was valued at USD 12.6 billion in 2025, is estimated at USD 14.1 billion in 2026 and is projected to reach USD 34.7 billion by 2034, a CAGR of 11.9% over 2026 to 2034.
What Is Life Sciences Data Intelligence?
It covers software platforms, curated datasets and analytics services that connect clinical, real-world, genomic, commercial and regulatory data for pharmaceutical, biotechnology, medical device and research organizations.
The market is moving from standalone databases and static reports toward connected, AI-ready platforms with embedded agents. Vendors are linking commercial, clinical and regulatory data on one architecture, adopting open standards such as HL7 FHIR, OMOP and CDISC, and offering governed access to de-identified patient data. Buyers now expect audit trails, data lineage and GxP-grade controls.
Growth Drivers
Licensed real-world and multimodal data. Drug developers use real-world data to find eligible patients, select trial sites, build external control arms and support payer discussions. Demand rises as therapies target smaller patient populations, where traditional recruitment and market sizing fall short. The Tempus AI agreements with AstraZeneca and Pathos AI to build a multimodal oncology foundation model, which include USD 200 million in data licensing and model development fees, show buyers paying directly for curated, de-identified data.
R&D complexity. Global trials must reconcile EDC, imaging, wearable and genomic inputs while meeting GxP and 21 CFR Part 11 expectations. Platforms that standardize these inputs to CDISC and OMOP models cut manual cleaning and shorten the gap between data lock and analysis. Oncology, rare disease and cell and gene therapy pipelines add further demand for linked, high-quality datasets.
Smarter commercial data. Commercial teams are replacing static prescriber lists with continuously updated reference data and patient-level insights. Specialty and rare disease launches need precise targeting of physicians, treatment centers and referral paths.
Policy momentum. The European Health Data Space Regulation (EU) 2025/327 entered into force on 26 March 2025 and creates a common legal framework for reusing electronic health data for research and policy. Secondary use provisions apply from March 2029, giving companies a defined timeline to prepare governance and analytics capabilities.
Key Trend: Agentic AI Enters Regulated Workflows
Vendors are moving beyond search and dashboards to agentic AI that completes defined tasks such as literature review, protocol feasibility checks and field-team call preparation. Each agent works inside the vendor’s governed environment, so outputs stay traceable to source records. This changes how pharma budgets for data, from per-seat access to workflow-based use.
Domain-trained language models, retrieval over curated content and tool-calling frameworks now sit on clinical, commercial and real-world datasets. Adoption is strongest among large pharmaceutical companies that have the volumes and governance teams to validate agent output.
Competitive advantage is shifting toward owners of proprietary, well-curated data, since agents are only as reliable as the records they read. Smaller vendors without unique data or deep workflow integration face pressure to partner or be acquired.
On the regulatory side, the FDA and EMA jointly published ten guiding principles for good AI practice in drug development, covering a risk-based approach, clear context of use, data governance and life cycle management. The FDA also launched Elsa, a generative AI tool used to speed up clinical protocol reviews, which strengthens the case for well-structured, submission-ready data.
Market Segmentation
By component. Software platforms lead, since cloud suites for CRM, clinical data capture, safety processing and data management are embedded in daily workflows and renewed on multi-year contracts. Validation under GxP and 21 CFR Part 11 makes switching costly. Cloud data platforms such as Databricks and Snowflake add to this base. Professional services are growing fastest, as companies need help turning platforms into working analytics and AI use cases, including data engineering, legacy migration and model validation. Data products are the third component.
By data source. Real-world data is the largest source, since claims, EHR and registry data inform decisions across the product life cycle. Genomic and omics data is growing fastest as precision medicine programs generate richer molecular datasets, with demand strongest in oncology and rare disease. Clinical trial data, commercial and sales data, and literature and patent data complete the segment.
By deployment. Cloud-based deployment leads, offering faster implementation, continuous releases and elastic computing for large genomic and claims datasets. Hybrid is growing fastest as sponsors keep identifiable data in regional or on-premises environments while running analytics and AI in the cloud, in line with GDPR and data residency rules.
By application. Commercial analytics holds the largest share because sales, marketing and market access teams were early adopters of licensed data. Clinical development is growing fastest, as sponsors apply data intelligence to protocol design, site selection, patient recruitment and trial monitoring. Other applications are drug discovery and research, regulatory and safety, and market access and pricing.
By end user. Pharmaceutical companies dominate with the broadest data portfolios and the most regulatory exposure. Biotechnology companies are growing fastest, since emerging firms building clinical-stage pipelines need data infrastructure early and cloud subscriptions remove large upfront costs. CROs, device makers and academic institutes complete the segment.
Regional Analysis
North America held 45% of the market in 2025. The US anchors the region with the largest concentration of pharma and biotech headquarters, deep claims and EHR datasets, and leading data and cloud providers. The FDA’s real-world evidence program and HIPAA de-identification standards shape how data is used and licensed.
Asia-Pacific is the fastest-growing region. Japan has the region’s most mature pharma data market, supported by its Next-Generation Medical Infrastructure Act. India is expanding through the Ayushman Bharat Digital Mission and the Digital Personal Data Protection Act, 2023. China is investing in trial capacity under its Personal Information Protection Law, and South Korea’s data law amendments allow pseudonymized data for research. Europe holds about 26%.
Competitive Landscape
The market is consolidated. Veeva Systems, IQVIA, Oracle, Clarivate, Dassault Systèmes, Norstella, Komodo Health, Tempus AI, Snowflake, Databricks, Certara, Benchling, Elsevier, Definitive Healthcare and Indegene are among the profiled players. Competition centers on data depth and quality, validated workflows, interoperability and the ability to embed AI inside regulated processes.
Recent developments:
- December 2025: Veeva announced AI Agents for Vault CRM and PromoMats.
- December 2025: Clarivate released its Cortellis Regulatory Intelligence AI Assistant.
- January 2026: Oracle announced the Oracle Life Sciences AI Data Platform.
- March 2026: IQVIA launched IQVIA.ai, a unified agentic AI platform developed with NVIDIA.
Acquisitions and partnerships are frequent, as software firms buy data and domain specialists and cloud companies partner with data owners.
Opportunities
- Submission-ready data products. Sponsors face rising expectations for structured, traceable data. Mid-size biotechs without in-house data engineering are an underserved buyer group.
- Regulatory and pharmacovigilance intelligence. Curated requirements, alerts and conversational access to guidance documents open recurring subscription lines.
- Emerging regions. Growing trial activity and local manufacturing create first-time demand for master data, trial analytics and cloud platforms, often through regional partnerships.
Takeaway
For pharma buyers, the priority is governed, AI-ready data with clear lineage. For vendors, proprietary data assets, GxP-grade compliance and open integration with cloud platforms will separate the leaders from the rest.
Frequently Asked Questions
1. What is the life sciences data intelligence market?
It covers software platforms, curated datasets and analytics services that connect clinical, real-world, genomic, commercial and regulatory data for life sciences organizations.
2. What is its size and growth rate?
USD 12.6 billion in 2025, expected to reach USD 34.7 billion by 2034 at an 11.9% CAGR.
3. Which component is growing fastest?
Professional services.
4. Who are the main end users?
Pharmaceutical companies are the largest. Biotechnology companies are growing fastest.
5. Why does the European Health Data Space matter?
It creates a common legal framework for reusing electronic health data for research, with secondary use provisions applying from March 2029.
📊 Want the Full Breakdown? Get the Sample Pages
Explore the complete report, with 170-180 pages and 55-65 market tables.
👉Download the free sample pages of the Life Sciences Data Intelligence Market report
Comments